Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Net revenue:
Total net revenue		$ 107,238	$ 114,760	$ 211,130	$ 211,253
Cost of revenue:
Total cost of revenue	[1]	71,336	71,793	135,735	133,689
Gross profit		35,902	42,967	75,395	77,564
Operating expenses:
Research and development	[2]	15,281	14,641	29,294	28,733
Selling and marketing		11,361	13,586	21,605	24,381
General and administrative		13,224	12,035	26,247	23,927
Total operating expenses		39,866	40,262	77,146	77,041
Income (loss) from operations		(3,964)	2,705	(1,751)	523
Income (loss) from equity method investment, net		(427)	(699)	4	(1,067)
Other expense, net		(4,352)	(2,831)	(8,033)	(5,389)
Loss before provision for income taxes		(8,743)	(825)	(9,780)	(5,933)
Provision for income taxes		878	1,049	2,810	1,390
Net loss		$ (9,621)	$ (1,874)	$ (12,590)	$ (7,323)
Net loss per share - basic		$ (0.1)	$ (0.02)	$ (0.13)	$ (0.08)
Net loss per share - diluted		$ (0.1)	$ (0.02)	$ (0.13)	$ (0.08)
Weighted average common shares used in computing net loss per share:
Basic		97,776	94,567	97,165	94,048
Diluted		97,776	94,567	97,165	94,048
Other comprehensive income (loss):
Net Income (Loss)		$ (9,621)	$ (1,874)	$ (12,590)	$ (7,323)
Foreign currency translation adjustment		2,773	2,790	635	(865)
Comprehensive income (loss)		(6,848)	916	(11,955)	(8,188)
Products
Net revenue:
Total net revenue	[3]	51,538	63,269	104,888	107,892
Cost of revenue:
Total cost of revenue		34,333	39,248	70,032	68,098
Services
Net revenue:
Total net revenue	[4]	55,700	51,491	106,242	103,361
Cost of revenue:
Total cost of revenue		$ 37,003	$ 32,545	$ 65,703	$ 65,591

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $11,102 and $26,373 during the three and six months ended December 31, 2023 and $9,916 and $15,823 during the three and six months ended December 31, 2022. respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $67 and $199 during the three and six months ended December 31, 2023 and $487 and $1,266 during the three and six months ended December 31, 2022, respectively.

[3] Includes sales of products to the joint venture, an equity method investment, of $17,890 and $39,842 during the three and six months ended December 31, 2023 and $16,715 and $25,584 during the three and six months ended December 31, 2022, respectively. See Note 13.

[4] Includes sales of services to the joint venture, an equity method investment, of $4,134 and $6,988 during the three and six months ended December 31, 2023 and $2,494 and $5,451 during the three and six months ended December 31, 2022, respectively. See Note 13.